1. Home
  2. VATE vs RLYB Comparison

VATE vs RLYB Comparison

Compare VATE & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INNOVATE Corp.

VATE

INNOVATE Corp.

HOLD

Current Price

$10.79

Market Cap

168.2M

Sector

Industrials

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$14.25

Market Cap

75.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VATE
RLYB
Founded
1994
2018
Country
United States
United States
Employees
N/A
14
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
168.2M
75.9M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
VATE
RLYB
Price
$10.79
$14.25
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
53.4K
289.2K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,246,000,000.00
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.55
43.00
52 Week Low
$3.75
$0.27
52 Week High
$13.46
$15.31

Technical Indicators

Market Signals
Indicator
VATE
RLYB
Relative Strength Index (RSI) 49.62 80.20
Support Level $4.47 $0.54
Resistance Level $13.40 $15.31
Average True Range (ATR) 0.97 0.71
MACD -0.35 0.23
Stochastic Oscillator 20.39 83.84

Price Performance

Historical Comparison
VATE
RLYB

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: